Cellular Therapy involves utilization of cells for treatment including haematopoietic stem cell transplantation (HSCT). HSCT may enable stem and progenitor cells to be engrafted, replacing the bone marrow of the recipient completely. Other examples include bone marrow-derived mesenchymal stromal cells, embryonic or induced pluripotent stem cells (iPs) and specific T-lymphocytic cell lines which can differentiate into a variety of cells. In the future this might also include the ex-vivo expansion of cord blood into red blood cells, platelets and their progenitors. Novel blood-derived therapeutics include platelet lysates, amniopatch and serum eye drops.
We cover all the different aspects of (novel) cellular therapies. We foster collaboration amongst ISBT members, promote investigation and initiate projects including guidelines and standards. We act as an expert group to advise ISBT and cooperate with the AABB Cell therapy Working Group. We provide a platform for discussion, especially when related to transfusion and provide a resource for learning and the exchange of ideas.
Our Chairperson is Mickey Koh.
We meet at the ISBT congresses and initiate collaborative projects. We advise and represent ISBT on global issues regarding cellular therapy and collaborate with AABB's Cellular Therapy Group.
Our WP currently comprises mostly of medical professionals including haemato-oncologists, infectious disease experts, doctors, nurses and scientists working in the area of cell and tissue regeneration. But other interested individuals (regulatory affairs, specialized nurses, quality managers or scientists) are also eligible to join.
Interested in joining the Cellular Therapies WP? Please email our Chairperson.
Some of the content is only accessible for ISBT-members.
To join us, click here.
Our main aim is to bring current and best practices in cellular therapy to transfusion professionals. Please find below some topics where we work on supporting you with material and ideas.